echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BJU Int: a population-based randomized trial of clinically significant prostate cancer screening

    BJU Int: a population-based randomized trial of clinically significant prostate cancer screening

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    General principles of cancer screening include the detection of clinically significant disease in an asymptomatic population with known natural progression, and early diagnosis and treatment that are effective in improving outcomes and reducing mortality


    Recently, researchers from Finland published an article in BJU Int evaluating the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel and multiparametric magnetic resonance imaging (MRI).


    Evaluated the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel, and multiparametric magnetic resonance imaging (MRI) and aimed to minimize overdiagnosis while preserving mortality benefits Evaluated the feasibility of a population-based screening test using prostate-specific antigen (PSA), kallikrein panel, and multiparametric magnetic resonance imaging (MRI) and aimed to minimize overdiagnosis while preserving mortality benefits

    The researchers evaluated the feasibility of the screening algorithm in terms of engagement, screening test results, and cancer detection


    Of the 399 men invited, 158 (40%) participated in the trial, of whom 27 had PSA levels ≥3 ng/mL (7% of invitees, 17% of participants)


    Thus, additional testing (kallikrein panel and MRI) after PSA reduced biopsy rates by 56%


    Outcomes of men with cancer screened in the study

    Outcomes of men with cancer screened in the study

     

    Taken together, their results demonstrate that their screening protocol is effective, substantially reducing the proportion of biopsies


    Their results demonstrate that their screening protocol is effective, resulting in a substantial reduction in the proportion of biopsies

     

    Original source:

    Original source:

    Antti Rannikko, Mare Leht, Tuomas Mirtti et al.


     



    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.